The autonomic nervous system and hypertension

Circulation Research

Volumn 114, Issue 11, 2014, Pages 1804-1814

  Mancia, Giuseppe ^a,b   Grassi, Guido ^b,c  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

hypertension; parasympathetic nervous system; sympathetic nervous system

Indexed keywords

ANTIHYPERTENSIVE THERAPY; AUTONOMIC DYSFUNCTION; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR DISEASE; ESSENTIAL HYPERTENSION; HUMAN; HYPERACTIVITY; HYPERTENSION; PREHYPERTENSION; PRIORITY JOURNAL; REVIEW; SYMPATHETIC FUNCTION; SYMPATHETIC TONE;

HYPERTENSION; PARASYMPATHETIC NERVOUS SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; DISEASE PROGRESSION; HUMANS; HYPERTENSION; SYMPATHETIC NERVOUS SYSTEM; VAGUS NERVE;

EID: 84901445372     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.302524     Document Type: Review

References (120)

1. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982;62:347-504.
2. Oparil S. The sympathetic nervous system in clinical and experimental hypertension. Kidney Int. 1986;30:437-452.
3. Mark AL. The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure. J Hypertens Suppl. 1996;14:S159-S165.
4. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999;34:724-728.
5. Palatini P, Julius S. The role of cardiac autonomic function in hypertension and cardiovascular disease. Curr Hypertens Rep. 2009;11:199-205.
6. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009;54:690-697.
7. Esler M. Sympathetic nervous system moves toward center stage in cardiovascular medicine: from Thomas Willis to resistant hypertension. Hypertension 2014;63:e25-e32.
8. De Leeuw PW. Secondary hypertension: diagnosis and treatment. In: Mancia G, Grassi G, Kjeldsen SE, eds. Manual of Hypertension of the European Society of Hypertension London: Informa Healthcare; 2008:255-262.
9. McCrory WW, Klein AA, Rosenthal RA. Blood pressure, heart rate, and plasma catecholamines in normal and hypertensive children and their siblings at rest and after standing. Hypertension 1982;4:507-513.
10. Horikoshi Y, Tajima I, Igarashi H, Inui M, Kasahara K, Noguchi T. The adreno-sympathetic system, the genetic predisposition to hypertension, and stress. Am J Med. Sci. 1985;289:186-191.
11. Ferrara LA, Moscato TS, Pisanti N, Marotta T, Krogh V, Capone D, Mancini M. Is the sympathetic nervous system altered in children with familial history of arterial hypertension? Cardiology 1988;75:200-205.
12. Perini C, Müller FB, Rauchfleisch U, Battegay R, Hobi V, Bühler FR. Psychosomatic factors in borderline hypertensive subjects and offspring of hypertensive parents. Hypertension 1990;16:627-634.
13. Bianchetti MG, Weidmann P, Beretta-Piccoli C, Rupp U, Boehringer K, Link L, Ferrier C. Disturbed noradrenergic blood pressure control in normotensive members of hypertensive families. Br Heart J. 1984;51:306-311.
14. Singh JP, Larson MG, Manolio TA, O'Donnell CJ, Lauer M, Evans JC, Levy D. Blood pressure response during treadmill testing as a risk factor for new-onset hypertension. The Framingham heart study. Circulation 1999;99:1831-1836.
15. Matthews CE, Pate RR, Jackson KL, Ward DS, Macera CA, Kohl HW, Blair SN. Exaggerated blood pressure response to dynamic exercise and risk of future hypertension. J Clin Epidemiol. 1998;51:29-35.
16. Ferrier C, Cox H, Esler M. Elevated total body noradrenaline spillover in normotensive members of hypertensive families. Clin Sci (Lond). 1993;84:225-230.
17. Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Shionoiri H, Ishii M, Kaneko Y. Impaired baroreflex changes in muscle sympathetic nerve activity in adolescents who have a family history of essential hypertension. J Hypertens Suppl. 1988;6:S525-S528.
18. Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA. Sympathetic neural mechanisms in white-coat hypertension. J Am Coll Cardiol. 2002;40:126-132.
19. Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens. 2004;17:217-222.
20. Grassi G, Seravalle G, Trevano FQ, Dell'oro R, Bolla G, Cuspidi C, Arenare F, Mancia G. Neurogenic abnormalities in masked hypertension. Hypertension 2007;50:537-542.
21. Mancia G, Bombelli M, Sega R, Grassi G. White coat and masked hypertension. In: Black HR, Elliott WJ, eds. Hypertension A Companion to Braunwald's Heart Disease. Saunders Elsevier: Philadelphia, PA; 2012:64-68.
22. Piccirillo G, Viola E, Nocco M, Durante M, Tarantini S, Marigliano V. Autonomic modulation of heart rate and blood pressure in normotensive offspring of hypertensive subjects. J Lab Clin Med. 2000;135:145-152.
23. Maver J, Struci M, Accetto R. Autonomic nervous system in normotensive subjects with a family history of hypertension. Clin Auton Res. 2004;14:369-375.
24. Hedman AE, Hartikainen JE, Tahvanainen KU, Hakumäki MO. The high frequency component of heart rate variability reflects cardiac parasympathetic modulation rather than parasympathetic 'tone.' Acta Physiol Scand. 1995;155:267-273.
25. Julius S, Krause L, Schork NJ, Mejia AD, Jones KA, van de Ven C, Johnson EH, Sekkarie MA, Kjeldsen SE, Petrin J. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens. 1991;9:77-84.
26. Julius S, Pascual AV, London R. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation 1971;44:413-418.
27. Julius S, Randall OS, Esler MD, Kashima T, Ellis C, Bennett J. Altered cardiac responsiveness and regulation in the normal cardiac output type of borderlind hlpertension. Circ Res. 1975;36:199-207.
28. Böhm R, van Baak M, van Hooff M, Moy J, Rahn KH. Salivary flow in borderline hypertension. Klin Wochenschr. 1985;63(suppl 3):154-156.
29. Esler M, Lambert G, Jennings G. Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens A. 1989;11(suppl 1):75-89.
30. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension 1988;14:1277-1283.
31. Floras JS, Hara K. Sympathoneural and haemodynamic characteristics of young subjects with mild essential hypertension. J Hypertens. 1993;11:647-655.
32. Hering D, Kara T, Kucharska W, Somers VK, Narkiewicz K. High-normal blood pressure is associated with increased resting sympathetic activity but normal responses to stress tests. Blood Press. 2013;22:183-187.
33. Bachmann AW, Ballantine DM, Gordon RD. Effect of positive family history of hypertension on the blood pressure and catecholamine responses to a 6 hour adrenaline infusion. Clin Exp Pharmacol Physiol. 1993;20:395-398.
34. Blankestijn PJ, Manin't Veld AJ, Tulen J, van den Meiracker AH, Boomsma F, Moleman P, Ritsema van Eck HJ, Derkx FH, Mulder P, Lamberts SJ. Support for adrenaline-hypertension hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion. Lancet 1988;2:1386-1389.
35. Brodde OE, Daul A, O'Hara N, Bock KD. Increased density and responsiveness of alpha 2 and beta-adrenoceptors in circulating blood cells of essential hypertensive patients. J Hypertens Suppl. 1984;2:S111-S114.
36. Brodde OE. Beta-adrenoceptors in cardiac disease. Pharmacol Ther. 1993;60:405-430.
37. Valentini M, Julius S, Palatini P, Brook RD, Bard RL, Bisognano JD, Kaciroti N. Attenuation of the haemodynamic, metabolic and energy responses to iosproterenol in patients with hypertension, J Hypertens. 2004;22:1999-2006.
38. Grassi G, Seravalle G, Stella ML, Mancia G. Pathophysiological aspects of hypertensive heart disease in women. J Hypertens. 2002;20(suppl 2):S6-S10.
39. Narkiewicz K, Phillips BG, Kato M, Hering D, Bieniaszewski L, Somers VK. Gender-selective interaction between aging, blood pressure, and sympathetic nerve activity. Hypertension 2005;45:522-525.
40. Grassi G, Seravalle G, Bertinieri G, Turri C, Dell'Oro R, Stella ML, Mancia G. Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. J Hypertens. 2000;18:587-593.
41. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998;31:68-72.
42. Schobel HP, Fischer T, Heuszer K, Geiger H, Schmieder RE. Preeclampsia-a state of sympathetic overactivity. N Engl J Med. 1996;335:1480-1485.
43. Grassi G, Seravalle G, Dell'Oro R, Turri C, Bolla GB, Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000;36:538-542.
44. Grassi G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Seravalle G, Paleari F, Gamba PL, Mancia G. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005;48:1359-1365.
45. Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003;108:3097-3101.
46. Brands MW, Hall JE. Insulin resistance, hyperinsulinemia, and obesityassociated hypertension. J Am Soc Nephrol. 1992;3:1064-1077.
47. Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997;96:4104-4113.
48. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, Trevano FQ, Grassi G, Zanchetti A, Sega R. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007;49:40-47.
49. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bombelli M, Cuspidi C, Facchetti R, Bolla G, Mancia G. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension 2008;52:925-931.
50. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368-2374.
51. Imai Y. Prognostic significance of ambulatory blood pressure. Blood Press Monit. 1999;4:249-256.
52. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912-1918.
53. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation 2002;106:1974-1979.
54. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol. 2003;14:3239-3244.
55. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell'Oro R, Mancia G. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011;57:846-851.
56. Greenwood JP, Scott EM, Stoker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol. 2001;38:1711-1717.
57. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003;108:560-565.
58. Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DA, Greenwood JP. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation 2007;115:1999-2005.
59. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Arenare F, Spaziani D, Mancia G. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension 2009;53:205-209.
60. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bolla G, Mancia G. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension 2003;42:873-877.
61. Grassi G, Seravalle G, Dell'Oro R, Facchini A, Ilardo V, Mancia G. Sympathetic and baroreflex function in hypertensive or heart failure patients with ventricular arrhythmias. J Hypertens. 2004;22:1747-1753.
62. Seravalle G, Volpe M, Ganz F, Magni L, Brambilla G, Dell'Oro R, Bombelli M, Mancia G, Grassi G. Neuroadrenergic profile in patients with resistant hypertension. J Hypertens. 2011;29:e141. (abstract).
63. Calhoun DA, Booth JN 3rd, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, populationbased cohort. Hypertension 2014;63:451-458.
64. Mancia G, Bonazzi O, Pozzoni L, Ferrari A, Gardumi M, Gregorini L, Perondi R. Baroreceptor control of atrioventricular conduction in man. Circ Res. 1979;44:752-758.
65. Grassi G, Colombo M, Seravalle G, Spaziani D, Mancia G. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension 1998;31:64-67.
66. Grassi G, Seravalle G, Brambilla G, Buzzi S, Volpe M, Cesana F, Dell'oro R, Mancia G. Regional differences in sympathetic activation in lean and obese normotensive individuals with obstructive sleep apnoea. J Hypertens. 2014;32:383-388.
67. Grassi, Seravalle G, Arenare F, Buccianti G, Furiani S, Ilardo V, Bolla G, Mancia G. Behaviour of regional adrenergic outflow in mild-to-moderate renal failure. J Hypertens. 2009;27:562-566.
68. Grassi G, Vailati S, Bertinieri G, Seravalle G, Stella ML, Dell'Oro R, Mancia G. Heart rate as marker of sympathetic activity. J Hypertens. 1998;16:1635-1639.
69. Chen L, Xin X, Eckhart AD, Yang N, Faber JE. Regulation of vascular smooth muscle growth by alpha 1-adrenoreceptor subtypes in vitro and in situ. J Biol Chem. 1995;270:30980-30988.
70. Hansson GK. How to chew up cells: lessons for the atherosclerotic plaque. Circ Res. 2012;111:669-671.
71. Bevan RD, Tsuru H. Functional and structural changes in the rabbit ear artery after sympathetic denervation. Circ Res. 1981;49:478-485.
72. Mangoni AA, Mircoli L, Giannattasio C, Mancia G, Ferrari AU. Effect of sympathectomy on mechanical properties of common carotid and femoral arteries. Hypertension 1997;30:1085-1088.
73. Sen S, Tarazi RC, Khairallah PA, Bumpus FM. Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res. 1974;35:775-781.
74. Failla M, Grappiolo A, Emanuelli G, Vitale G, Fraschini N, Bigoni M, Grieco N, Denti M, Giannattasio C, Mancia G. Sympathetic tone restrains arterial distensibility of healthy and atherosclerotic subjects. J Hypertens. 1999;17:1117-1123.
75. Giannattasio C, Mancia G. Arterial distensibility and the sympathetic nervous system. In: Safar ME, O'Rourke MF, eds. Handbook of Hypertension, Volume 23. Arterial Stiffness in Hypertension Amsterdam: Elsevier; 2006:213-224.
76. Mancia G. Short-term and long-term blood pressure variability. In: Berbari AE, Mancia G, eds. Special Issues in Hypertension Milan: Springer; 2012:91-102.
77. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
78. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J. 2001;22:1136-1143.
79. Sander D, Winbeck K, Klingelhöfer J, Etgen T, Conrad B. Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology. 2001;57:833-838.
80. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS, Cateliotti A. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002;105:1354-1359.
81. Barretto AC, Santos AC, Munhoz R, Rondon MU, Franco FG, Trombetta IC, Roveda F, de Matos LN, Braga AM, Middlekauff HR, Negrão CE. Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. Int J Cardiol. 2009;135:302-307.
82. Andreas S, Haarmann H, Klarner S, Hasenfuss G, Raupach T. Increased sympathetic nerve activity in COPD is associated with morbidity and mortality. Lung. 2014;192:235-241.
83. Penne EL, Neumann J, Klein IH, Bots ML, Blankestein PJ. Sympathetic hyperactivity and clinical outcome in chronic kidney disease during standard treatment. J Nephrol. 2009;22:208-215.
84. Julius S, Sanchez R, Malayan S, Hamlin M, Elkins M, Brant D, Bohr DF. Sustained blood pressure elevation to lower body compression in pigs and dogs. Hypertension 1982;4:782-788.
85. Fagard R, Grassi G. Blood pressure response to acute physical and mental stress. In: Mancia G, Grassi G, Kjeldsen SE, eds. Manual of Hypertension of the European Society of Hypertension London: Informa Healthcare; 2008:184-189.
86. Mancia G, Mark AL. Arterial baroreflexes in humans. In: Shepherd JT, Abboud FM, eds. Handbook of Physiology, Section 2: The Cardiovascular System. Bethesda, MD: American Physiological Society; 1983:755-793.
87. Ramirez AJ, Bertinieri G, Belli L, Cavallazzi A, Di Rienzo M, Pedotti A, Mancia G. Reflex control of blood pressure and heart rate by arterial baroreceptors and by cardiopulmonary receptors in the unanaesthetized cat. J Hypertens. 1985;3:327-335.
88. Cowley AW Jr. Long-term control of arterial blood pressure. Physiol Rev. 1992;72:231-300.
89. Grassi G, Giannattasio C, Cléroux J, Cuspidi C, Sampieri L, Bolla GB, Mancia G. Cardiopulmonary reflex before and after regression of left ventricular hypertrophy in essential hypertension. Hypertension 1988;12:227-237.
90. Trzebski A. Arterial chemoreceptor reflex and hypertension. Hypertension 1992;19:562-566.
91. Malliani A. Cardiovascular sympathetic afferent fibers. Rev Physiol Biochem Pharmacol. 1982;94:11-74.
92. Somers VK, Mark AL, Abboud FM. Sympathetic activation by hypoxia and hypercapnia-implications for sleep apnea. Clin Exp Hypertens A. 1988;(10 suppl 1):413-422.
93. Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension 2003;42:1067-1074.
94. Calaresu FR, Stella A, Zanchetti A. Haemodynamic responses and renin release during stimulation of afferent renal nerves in the cat. J Physiol. 1976;255:687-700.
95. DiBona GF. Physiology in perspective: the Wisdom of the Body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289:R633-R641.
96. Xu J, Hering D, Sata Y, Walton A, Krum H, Esler MD, Schlaich MP. Renal denervation: current implications and future perspectives. Clin Sci (Lond). 2014;126:41-53.
97. Mark AL, Correia M, Morgan DA, Shaffer RA, Haynes WG. State-ofthe-art-lecture: obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension 1999;33:537-541.
98. Saino A, Pomidossi G, Perondi R, Valentini R, Rimini A, Di Francesco L, Mancia G. Intracoronary angiotensin II potentiates coronary sympathetic vasoconstriction in humans. Circulation 1997;96:148-153.
99. Saino A, Pomidossi G, Perondi R, Morganti A, Turolo L, Mancia G. Modulation of sympathetic coronary vasoconstriction by cardiac renin-angiotensin system in human coronary heart disease. Circulation 2000;101:2277-2283.
100. Masuo K, Mikami H, Ogihara T, Tuck ML. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens. 1997;10:77-83.
101. Grassi G, Seravalle G, Stella ML, Turri C, Zanchetti A, Mancia G. Sympathoexcitatory responses to the acute blood pressure fall induced by central or peripheral antihypertensive drugs. Am J Hypertens. 2000;13:29-34.
102. Grassi G. Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens. 2004;13:513-519.
103. Van Zwieten P. Beneficial interactions between pharmacological, pathophysiological and hypertension research. J Hypertens. 2001;19:465-473.
104. Grassi G, Seravalle G, Calhoun DA, Mancia G. Physical training and baroreceptor control of sympathetic nerve activity in humans. Hypertension 1994;23:294-301.
105. Grassi G, Seravalle G, Colombo M, Bolla G, Cattaneo BM, Cavagnini F, Mancia G. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998;97:2037-2042.
106. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Bolla G, Mancia G. Baroreflex impairment by low sodium diet in mild or moderate essential hypertension. Hypertension 1997;29:802-807.
107. Grassi G, Dell'Oro R, Seravalle G, Foglia G, Trevano FQ, Mancia G. Short-and long-term neuroadrenergic effects of moderate dietary sodium restriction in essential hypertension. Circulation 2002;106:1957-1961.
108. Pal GK, Adithan C, Dutta TK, Pal P, Nanda N, Syamsundara Kiran AN, Lalitha V, Amudharaj D. Preference for salt contributes to sympathovagal imbalance in the genesis of prehypertension. Eur J Clin Nutr. 2013;67:586-591.
109. Menne J, Jordan J, Linnenweber-Held S, Haller H. Resistant hypertension: baroreflex stimulation as a new tool. Nephrol Dial Transplant. 2013;28:288-295.
110. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010;55:619-626.
111. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C. ESH position paper: renal denervation-an interventional therapy of resistant hypertension. J Hypertens. 2012;30:837-841.
112. Schlaich MP, Schmieder RE, Bakris G, et al. International Expert Consensus statement: percutaneous transluminal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62:2031-2045.
113. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, Haller H, Sweep FC, Diedrich A, Jordan J, Tank J. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficultto-control hypertensive patients: prospective case series. Hypertension 2012;60:1485-1490.
114. Fadl Elmula FE, Hoffmann P, Fossum E, Brekke M, Gjønnæss E, Hjørnholm U, Kjær VN, Rostrup M, Kjeldsen SE, Os I, Stenehjem AE, Høieggen A. Renal sympathetic denervation in patients with treatmentresistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 2013;62:526-532.
115. Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, Gjønnæss E, Hjørnholm U, Kjær VN, Rostrup M, Os I, Stenehjem A, Høieggen A. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 2014;63:991-999.
116. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401.
117. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932-934.
118. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-1281.
119. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013;61:457-464.
120. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (AALHAT). JAMA 2000;283:1967-1975.